Roz Brant
YOU?
Author Swipe
View article: Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Open
Supplemental Table 1: Design of Affymetrix and NanoString probes Supplemental Table 2: Genes included in the NanoString Codeset, including genes up- and down-regulated by MEK, Cres and KRAS signatures, plus housekeeper genes Supplemental T…
View article: Data from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Data from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Open
Purpose: To develop a clinically viable gene expression assay to measure RAS/RAF/MEK/ERK (RAS–ERK) pathway output suitable for hypothesis testing in non–small cell lung cancer (NSCLC) clinical studies.Experimental Design: A published MEK f…
View article: Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Open
Supplemental Table 1: Design of Affymetrix and NanoString probes Supplemental Table 2: Genes included in the NanoString Codeset, including genes up- and down-regulated by MEK, Cres and KRAS signatures, plus housekeeper genes Supplemental T…
View article: Data from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Data from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Open
Purpose: To develop a clinically viable gene expression assay to measure RAS/RAF/MEK/ERK (RAS–ERK) pathway output suitable for hypothesis testing in non–small cell lung cancer (NSCLC) clinical studies.Experimental Design: A published MEK f…
View article: Supplemental Figure 4 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 4 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Supplemental Figure 4A: Mean FOV and Mean % endogenous gene raw count between the first test (month 0) and the last test (month 9) shown to illustrate effect of storage of a cartridge at 4ºC over a nine month period. Mean raw counts were d…
View article: Supplemental Figure 2 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 2 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Heatmap showing unsupervised hierarchical clustering of matching clinical DLBCL Fresh, Frozen and FFPE tissues with a CodeSet consisting of 320 genes including 33 housekeeping genes. Genes below the LOD were omitted from the analysis.
View article: Data from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Data from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Analysis of clinical trial specimens such as formalin-fixed paraffin-embedded (FFPE) tissue for molecular mechanisms of disease progression or drug response is often challenging and limited to a few markers at a time. This has led to the i…
View article: Supplemental Table 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Table 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Summary of standard deviation calculations based on human Reference RNA sample replicates (R) tested independently on two Prep Stations (S1 and S2). The standard deviation calculations (based on log2 data) are measured as the difference fo…
View article: Supplemental Figure 4 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 4 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Supplemental Figure 4A: Mean FOV and Mean % endogenous gene raw count between the first test (month 0) and the last test (month 9) shown to illustrate effect of storage of a cartridge at 4ºC over a nine month period. Mean raw counts were d…
View article: Data from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Data from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Analysis of clinical trial specimens such as formalin-fixed paraffin-embedded (FFPE) tissue for molecular mechanisms of disease progression or drug response is often challenging and limited to a few markers at a time. This has led to the i…
View article: Supplemental Figure 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Supplemental Figure 1A: Variability due to number of FOV captured. A total of 287 genes were ranked on expression level and grouped as LOW, MEDIUM or HIGH expression for each FOV category. The Standard Deviation (SD) is calculated from mea…
View article: Supplemental Figure 3 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 3 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Correlation scatter plot of normalised log2 counts of UHR sample tested at 100ng in input volume of 5ul versus 100ng in input volume of 15ul with a CodeSet consisting of 463 including 18 housekeeping genes.
View article: Supplemental Figure 5 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 5 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Supplemental Figure 5A: Correlation scatter plot of normalised log2 values illustrating stability of a CodeSet after expiry date. A CodeSet consisting of 30 genes including 4 housekeeping genes was tested with a set of 6 identical samples …
View article: Supplemental Figure 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Supplemental Figure 1A: Variability due to number of FOV captured. A total of 287 genes were ranked on expression level and grouped as LOW, MEDIUM or HIGH expression for each FOV category. The Standard Deviation (SD) is calculated from mea…
View article: Supplemental Table 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Table 1 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Summary of standard deviation calculations based on human Reference RNA sample replicates (R) tested independently on two Prep Stations (S1 and S2). The standard deviation calculations (based on log2 data) are measured as the difference fo…
View article: Supplemental Figure 5 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 5 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Supplemental Figure 5A: Correlation scatter plot of normalised log2 values illustrating stability of a CodeSet after expiry date. A CodeSet consisting of 30 genes including 4 housekeeping genes was tested with a set of 6 identical samples …
View article: Supplemental Figure 6 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 6 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Correlation scatter plot of a representative lung cell line (NCI-H520) showing correlation of 118 overlapping genes in non-identical Codesets. An unusual outlier is marked with a circle. Data was normalised against 8 housekeeping genes.
View article: Supplemental Figure 2 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 2 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Heatmap showing unsupervised hierarchical clustering of matching clinical DLBCL Fresh, Frozen and FFPE tissues with a CodeSet consisting of 320 genes including 33 housekeeping genes. Genes below the LOD were omitted from the analysis.
View article: Supplemental Figure 6 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 6 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Correlation scatter plot of a representative lung cell line (NCI-H520) showing correlation of 118 overlapping genes in non-identical Codesets. An unusual outlier is marked with a circle. Data was normalised against 8 housekeeping genes.
View article: Supplemental Figure 3 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Supplemental Figure 3 from Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Open
Correlation scatter plot of normalised log2 counts of UHR sample tested at 100ng in input volume of 5ul versus 100ng in input volume of 15ul with a CodeSet consisting of 463 including 18 housekeeping genes.
View article: Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma Open
Background Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survi…
View article: Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer Open
MEK inhibitor (selumetinib) is a potent, orally active inhibitor of MAPK/ERK pathway. It is important to develop an accurate and robust method indicative of RAS pathway activity to stratify potential patients who can benefit from selumetin…